Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
$0.98
-16.2%
$1.06
$0.50
$10.50
$2.69M1.453.02 million shs596,319 shs
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
$0.29
$0.33
$0.27
$1.58
$4.47M1.03188,949 shs11,702 shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$2.74
-0.7%
$3.93
$2.60
$70.00
$15.10M0.11273,660 shs411,584 shs
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$2.46
-4.3%
$4.11
$2.37
$48.79
$7.33M7.94186,865 shs52,494 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
-10.00%-35.71%+2.63%+13.59%-84.52%
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
-2.00%-8.16%-0.99%-5.15%-68.92%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
+1.47%-6.12%-7.38%-32.85%-92.03%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-3.02%-3.38%-44.61%-50.19%-70.95%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
N/AN/AN/AN/AN/AN/AN/AN/A
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
N/AN/AN/AN/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
N/AN/AN/AN/A
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
3.00
BuyN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
$3.02M0.89N/AN/A($2.06) per share-0.48
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
N/AN/AN/AN/A$0.52 per shareN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.19M2.10N/AN/A($6.91) per share-0.40
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
$13.80M0.53N/AN/A$0.22 per share11.18

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
-$8.03M-$12.36N/AN/A-459.42%N/A-88.87%5/20/2024 (Estimated)
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
-$9.84MN/A0.00N/AN/A-103.10%-76.46%7/5/2024 (Estimated)
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-696.19%N/A-129.79%5/6/2024 (Confirmed)
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
-$13.58M-$11.05N/AN/A-98.42%-665.17%-122.48%6/13/2024 (Estimated)

Latest TTOO, STSS, VVOS, and INVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/A
3/29/2024Q4 2023
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
N/A-$0.16-$0.16-$0.16N/AN/A
3/28/2024Q4 2023
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/A-$3.05-$3.05-$3.05N/A$3.25 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
N/AN/AN/AN/AN/A
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
2.94
0.15
0.12
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
N/A
1.31
0.85
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.45
0.36
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
N/A
0.34
0.34

Ownership

Institutional Ownership

CompanyInstitutional Ownership
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
12.02%
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
17.17%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
26.35%

Insider Ownership

CompanyInsider Ownership
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
3.50%
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
14.10%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.10%
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
9.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
INVO Bioscience, Inc. stock logo
INVO
INVO Bioscience
152.74 million2.65 millionNo Data
Sharps Technology, Inc. stock logo
STSS
Sharps Technology
5715.67 million13.46 millionNot Optionable
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
1135.51 million5.51 millionOptionable
Vivos Therapeutics, Inc. stock logo
VVOS
Vivos Therapeutics
1542.98 million2.47 millionOptionable

TTOO, STSS, VVOS, and INVO Headlines

SourceHeadline
TELA Bio (NASDAQ:TELA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head AnalysisTELA Bio (NASDAQ:TELA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head Analysis
americanbankingnews.com - April 15 at 6:20 AM
Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approvalVivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval
proactiveinvestors.com - April 11 at 3:32 PM
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical DevicesVivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices
finance.yahoo.com - April 9 at 6:42 PM
Vivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral DevicesVivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral Devices
markets.businessinsider.com - April 9 at 1:41 PM
Whats Going On With Vivos Therapeutics Stock?What's Going On With Vivos Therapeutics Stock?
msn.com - April 9 at 1:41 PM
Medicare to reimburse for Vivos CARE sleep apnea devicesMedicare to reimburse for Vivos CARE sleep apnea devices
msn.com - April 9 at 1:41 PM
Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursementVivos Therapeutics CARE oral medical devices approved for Medicare reimbursement
proactiveinvestors.com - April 9 at 9:31 AM
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
investorplace.com - April 9 at 8:53 AM
Vivos Therapeutics files to sell 1.73M shares of common stock for holdersVivos Therapeutics files to sell 1.73M shares of common stock for holders
msn.com - April 9 at 8:41 AM
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementVivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
finance.yahoo.com - April 9 at 8:41 AM
Vivos Therapeutics Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementVivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
globenewswire.com - April 9 at 7:30 AM
Verve Therapeutics Pauses Enrollment in Cardiovascular Base-Editing Drug After Safety ReportVerve Therapeutics Pauses Enrollment in Cardiovascular Base-Editing Drug After Safety Report
precisionmedicineonline.com - April 2 at 5:52 PM
Vivos Therapeutics highlights path to cash flow positivity after FDA clearanceVivos Therapeutics highlights path to cash flow positivity after FDA clearance
proactiveinvestors.com - April 1 at 9:07 AM
Vivos Therapeutics Full Year 2023 Earnings: Misses ExpectationsVivos Therapeutics Full Year 2023 Earnings: Misses Expectations
finance.yahoo.com - March 31 at 1:42 PM
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call TranscriptVivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 30 at 12:38 PM
Vivos Therapeutics Shares Fall After Wider-Than-Expected 4Q LossVivos Therapeutics Shares Fall After Wider-Than-Expected 4Q Loss
marketwatch.com - March 29 at 1:13 AM
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
globenewswire.com - March 28 at 4:05 PM
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
globenewswire.com - March 28 at 7:30 AM
Vivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest Report
benzinga.com - February 22 at 12:09 PM
Vivos Therapeutics Stock (NASDAQ:VVOS) Insider TradesVivos Therapeutics Stock (NASDAQ:VVOS) Insider Trades
benzinga.com - February 22 at 7:09 AM
Vivos Therapeutics secures $4 million through warrant exerciseVivos Therapeutics secures $4 million through warrant exercise
investing.com - February 18 at 12:39 AM
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsVivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
finance.yahoo.com - February 15 at 9:27 AM
Vivos Therapeutics sees gross proceeds of $4M from exercise of warrantVivos Therapeutics sees gross proceeds of $4M from exercise of warrant
proactiveinvestors.com - February 15 at 9:13 AM
Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market DisruptionsVivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions
finance.yahoo.com - February 12 at 9:45 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

INVO Bioscience logo

INVO Bioscience

NASDAQ:INVO
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida.
Sharps Technology logo

Sharps Technology

NASDAQ:STSS
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
T2 Biosystems logo

T2 Biosystems

NASDAQ:TTOO
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Vivos Therapeutics logo

Vivos Therapeutics

NASDAQ:VVOS
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.